<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sarandakou, A.</style></author><author><style face="normal" font="default" size="100%">Phocas, I.</style></author><author><style face="normal" font="default" size="100%">Botsis, D.</style></author><author><style face="normal" font="default" size="100%">Sikiotis, K.</style></author><author><style face="normal" font="default" size="100%">Rizos, D.</style></author><author><style face="normal" font="default" size="100%">Kalambokis, D.</style></author><author><style face="normal" font="default" size="100%">Trakakis, E.</style></author><author><style face="normal" font="default" size="100%">Chryssikopoulos, A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Tumour-associated antigens CEA, CA125, SCC and TPS in gynaecological cancer</style></title><secondary-title><style face="normal" font="default" size="100%">European Journal of Gynaecological Oncology</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">breast cancer</style></keyword><keyword><style  face="normal" font="default" size="100%">CA125</style></keyword><keyword><style  face="normal" font="default" size="100%">CEA</style></keyword><keyword><style  face="normal" font="default" size="100%">Cervical adenocarcinoma</style></keyword><keyword><style  face="normal" font="default" size="100%">Cervical squamous cell carcinoma</style></keyword><keyword><style  face="normal" font="default" size="100%">Endometrial carcinoma</style></keyword><keyword><style  face="normal" font="default" size="100%">Ovarian cancer</style></keyword><keyword><style  face="normal" font="default" size="100%">SCC</style></keyword><keyword><style  face="normal" font="default" size="100%">TPS</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">1998</style></year><pub-dates><date><style  face="normal" font="default" size="100%">1998///</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">19</style></volume><pages><style face="normal" font="default" size="100%">73 - 77</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Pretreatment values of CEA, CA125, SCC and TPS were measured in 130 women with 1) ovarian carcinoma (n = 25), 2) breast cancer (n = 20), 3) endometrial cancer (n = 14), 4) cervical squamous cell carcinoma (n = 20), 5) cervical adenocarcinoma (n = 9) and 6) benign gynaecological diseases (n = 42) in order to evaluate the usefulness of multiple markers in diagnosing and monitoring patients with gynaecological cancer. Antigen values were significantly higher in the cancer groups than those in the benign one (p &lt; 0.0001). CEA values were significantly elevated in the 2nd and 5th groups, CA125 in the 1st and 5th, SCC in the 4th and 5th, and TPS in the 1st, 2nd and 5th compared to the remaining groups (p &lt; 0.04-p &lt; 0.0001). In advanced stage diseases, significantly higher antigen values, except for SCC, than those in limited rumours were measured (p &lt; 0.05-p &lt; 0.0001). In conclusion, our results suggest that, multiple markers may be more efficienti than the use of single markers in accurately identifying malignant from benign gynaecological diseases and in monitoring cancer patients.</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue></record></records></xml>